查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971858

基因靜默市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終用戶、組件、製程、模式、階段分類

Gene Silencing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Process, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 488 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

基因靜默市場預計將從2024年的46.6億美元成長到2034年的113.1億美元，複合年成長率約為9.3%。基因靜默市場涵蓋旨在抑制基因表現的技術和方法，例如RNA干擾和反義寡核苷酸。該市場支持遺傳疾病和癌症的研究和治療應用。在遺傳疾病日益增多和生物技術進步的推動下，遞送系統和特異性方面的創新至關重要。對個人化醫療和新型治療方法的需求正在推動市場成長，並促進生物技術公司和學術機構之間的合作。

基因靜默市場正經歷強勁成長，這主要得益於基因研究和治療應用領域的進步。 RNARNA干擾領域是市場的主要驅動力，其中小干擾RNA（siRNA）技術憑藉其精準的基因標靶化佔據主導。反義寡核苷酸（ASO）緊隨其後，這得益於其在各種條件下調控基因表現的多功能性。在RNA干擾領域，治療應用子領域表現最為強勁，為遺傳疾病和癌症的治療方法提供了極具前景的方案。研究應用子領域位居第二，主要得益於基因組研究投入的不斷增加。遞送技術領域也發展迅猛，脂質奈米顆粒因其遞送效率和安全性而成為基因靜默劑的首選載體。遞送系統的創新發展以及個人化醫療應用的不斷拓展進一步推動了市場成長。生技公司與研究機構之間的策略聯盟正在強化開發平臺，並為相關人員創造盈利的機會。

市場區隔
類型 短干擾RNA（siRNA）、微型RNA（miRNA）、短髮夾RNA（shRNA）、反義寡核苷酸（ASO）
產品 試劑、設備和試劑盒
服務 基因靜默研究、客製合成、諮詢
科技 RNA干擾（RNAi）、CRISPR-Cas9和反義技術
應用 藥物發現與開發、功能基因體學、疾病診斷、治療藥物
最終用戶 製藥公司、生技公司、學術研究機構、受託研究機構
成分 載體、轉染試劑及遞送載體
過程 體外、體內
模式 直接的，間接的
步 藥物發現、臨床前研究、臨床研究、商業化

市場概況：

基因靜默市場正經歷動態變化，主要產業參與者佔據了相當大的市場。定價策略日趨激烈，反映出新參與企業和創新科技的湧入。近期產品推出引進了先進的基因靜默技術，並增強了治療應用和研究能力。這造成了競爭異常激烈的市場環境，尤其是在研究經費和生技投資充裕的地區。市場格局的特點是產品供應的持續演變，而這主要由技術進步和策略聯盟所驅動。從競爭標竿分析的角度來看，產業領導企業正在大力投資研發以保持其優勢。法規結構，尤其是在北美和歐洲，對塑造市場動態至關重要。這些法規確保了安全性和有效性，並影響產品核可時間和打入市場策略。專利法和智慧財產權進一步影響競爭格局，它們對於維持創新和保護專有技術至關重要。市場前景廣闊，個人化醫療和RNA干擾技術預計將帶來成長機會。

主要趨勢和促進因素：

基因靜默市場正經歷強勁成長，這主要得益於基因研究和生物技術的進步。一個關鍵趨勢是RNA干擾（RNAi）技術在治療研發中的應用日益廣泛，為遺傳性疾病和慢性疾病提供了標靶治療方案。全球範圍內這些疾病的日益流行進一步推動了這一趨勢。另一個關鍵促進因素是製藥和生技公司不斷增加的研發投入。這些投入旨在發現新型基因靜默技術並拓展其治療應用。值得注意的是，基因靜默技術在農業生物技術領域的應用也日益增多，用於增強作物抗性和提高產量。主要市場的監管支持和有利政策也進一步促進了該行業的成長。學術機構和生技公司之間的合作也帶來了新的機遇，促進了創新並加速了基因靜默技術的商業化。隨著人們對精準醫療和個人化治療的認知不斷提高，基因靜默市場預計將持續擴張。

限制與挑戰：

基因靜默市場面臨許多重大限制與挑戰。首先，基因靜默技術高昂的研發成本對新參與企業構成重大障礙，並限制了現有企業的擴張。其次，監管障礙和嚴格的核准流程延緩了基因靜默產品的商業化進程，影響了市場成長。第三，倫理問題和公眾對基因修飾技術的擔憂阻礙了其廣泛應用。此外，基因靜默機制的複雜性需要專業知識，導致熟練人才短缺，並增加了對培訓和教育的需求。最後，技術的快速發展需要持續的創新和改進投入，這可能導致資源緊張，並減緩市場發展。這些挑戰共同阻礙了基因靜默解決方案的擴充性和廣泛應用。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 短干擾RNA（siRNA）
    • 微型RNA（miRNA）
    • 短髮夾RNA（shRNA）
    • 反義寡核苷酸（ASO）
  • 市場規模及預測：依產品分類
    • 試劑
    • 裝置
    • 成套工具
  • 市場規模及預測：依服務分類
    • 基因靜默研究
    • 客製合成
    • 諮詢
  • 市場規模及預測：依技術分類
    • RNA干擾（RNAi）
    • CRISPR-Cas9
    • 反義技術
  • 市場規模及預測：依應用領域分類
    • 藥物發現與開發
    • 功能基因體學
    • 疾病診斷
    • 治療藥物
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 學術研究機構
    • 合約研究機構
  • 市場規模及預測：依組件分類
    • 向量
    • 轉染試劑
    • 遞送載體
  • 市場規模及預測：依製程分類
    • 體外
    • In vivo
  • 市場規模及預測：以作用方式分類
    • 直接的
    • 間接
  • 市場規模及預測：依發展階段分類
    • 藥物發現
    • 臨床前階段
    • 臨床
    • 商業的

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Alnylam Pharmaceuticals
  • Ionis Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Silence Therapeutics
  • Dicerna Pharmaceuticals
  • Arcturus Therapeutics
  • Benitec Biopharma
  • Marina Biotech
  • Quark Pharmaceuticals
  • Sirnaomics
  • RXi Pharmaceuticals
  • Genevant Sciences
  • Calando Pharmaceuticals
  • Regulus Therapeutics
  • Gradalis
  • Atalanta Therapeutics
  • Stoke Therapeutics
  • Wave Life Sciences
  • ProQR Therapeutics
  • Bio-Path Holdings

第9章：關於我們

簡介目錄
Product Code: GIS33121

Gene Silencing Market is anticipated to expand from $4.66 billion in 2024 to $11.31 billion by 2034, growing at a CAGR of approximately 9.3%. The Gene Silencing Market encompasses technologies and methodologies aimed at suppressing gene expression, including RNA interference and antisense oligonucleotides. This market supports research and therapeutic applications, targeting genetic disorders and cancer. Innovations in delivery systems and specificity are pivotal, driven by the rising prevalence of genetic diseases and advancements in biotechnology. The demand for personalized medicine and novel treatments fuels growth, fostering partnerships between biotech firms and academic institutions.

The Gene Silencing Market is experiencing robust growth, fueled by advancements in genetic research and therapeutic applications. The RNA interference segment dominates, with small interfering RNA (siRNA) technologies leading due to their precision in gene targeting. Antisense oligonucleotides (ASOs) follow closely, driven by their versatility in modulating gene expression across various conditions. Within the RNA interference segment, the therapeutic application sub-segment is the top performer, as it offers promising treatments for genetic disorders and cancers. The research application sub-segment ranks second, supported by growing investments in genomic studies. The delivery technologies segment is also gaining momentum, with lipid nanoparticles being the preferred choice for their efficiency and safety in delivering gene silencing agents. Emerging innovations in delivery systems and expanding applications in personalized medicine further propel market growth. Strategic collaborations between biotech firms and research institutions enhance development pipelines, presenting lucrative opportunities for stakeholders.

Market Segmentation
TypeShort Interfering RNA (siRNA), MicroRNA (miRNA), Short Hairpin RNA (shRNA), Antisense Oligonucleotides (ASO)
ProductReagents, Instruments, Kits
ServicesGene Silencing Research, Custom Synthesis, Consultation
TechnologyRNA Interference (RNAi), CRISPR-Cas9, Antisense Technology
ApplicationDrug Discovery and Development, Functional Genomics, Disease Diagnostics, Therapeutics
End UserPharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations
ComponentVectors, Transfection Reagents, Delivery Vehicles
ProcessIn Vitro, In Vivo
ModeDirect, Indirect
StageDiscovery, Preclinical, Clinical, Commercial

Market Snapshot:

The Gene Silencing Market is witnessing a dynamic shift with significant market share held by key industry players. Pricing strategies are increasingly competitive, reflecting the influx of new entrants and innovations. Recent product launches have introduced advanced gene silencing technologies, enhancing therapeutic applications and research capabilities. This is fostering a robust competitive environment, particularly in regions with substantial research funding and biotech investments. The market landscape is characterized by a continuous evolution of product offerings, driven by technological advancements and strategic collaborations. In terms of competition benchmarking, industry leaders are investing heavily in R&D to maintain their edge. Regulatory frameworks, particularly in North America and Europe, are pivotal in shaping market dynamics. These regulations ensure safety and efficacy, impacting product approval timelines and market entry strategies. The competitive landscape is further influenced by patent laws and intellectual property rights, which are critical in sustaining innovation and protecting proprietary technologies. The market's trajectory is promising, with opportunities for growth in personalized medicine and RNA interference technologies.

Geographical Overview:

The gene silencing market is witnessing robust growth across various regions, each characterized by unique dynamics. North America leads, propelled by advanced research facilities and substantial investments in biotechnology. The region's focus on personalized medicine and genetic research further accelerates market expansion. Europe follows, with strong regulatory support and funding for genetic research fostering a thriving gene silencing ecosystem. The emphasis on innovation and collaboration among European nations enhances market potential. In Asia Pacific, rapid technological advancements and increasing healthcare expenditures drive significant market growth. Countries like China and India are emerging as key players, investing heavily in biotechnology and genomics. Latin America and the Middle East & Africa are nascent markets with growing opportunities. In Latin America, rising awareness and investments in genetic research are notable. Meanwhile, the Middle East & Africa are recognizing the potential of gene silencing in addressing region-specific health challenges, paving the way for future growth.

Key Trends and Drivers:

The gene silencing market is experiencing robust growth, propelled by advancements in genetic research and biotechnology. A key trend is the increasing application of RNA interference (RNAi) technology in therapeutic development, offering targeted treatment options for genetic disorders and chronic diseases. This trend is accelerated by the rising prevalence of such conditions globally. Another significant driver is the growing investment in research and development by pharmaceutical and biotechnology companies. These investments are aimed at discovering novel gene silencing techniques and expanding their therapeutic applications. Additionally, the expanding use of gene silencing in agricultural biotechnology to enhance crop resistance and productivity is noteworthy. Regulatory support and favorable policies in major markets are further bolstering the industry's growth. Opportunities are also arising from collaborations between academic institutions and biotech firms, fostering innovation and accelerating the commercialization of gene silencing technologies. As awareness of precision medicine and personalized therapies increases, the gene silencing market is poised for sustained expansion.

Restraints and Challenges:

The gene silencing market encounters several significant restraints and challenges. Firstly, the high cost of research and development in gene silencing technologies presents a substantial barrier to entry for new companies and limits the expansion of existing firms. Secondly, regulatory hurdles and stringent approval processes delay the commercialization of gene silencing products, impacting market growth. Thirdly, ethical concerns and public apprehension surrounding genetic modification technologies pose a challenge to widespread acceptance and adoption. Additionally, the complexity of gene silencing mechanisms requires specialized knowledge, limiting the pool of skilled professionals and increasing the demand for training and education. Finally, the rapid pace of technological advancement necessitates continuous investment in innovation and adaptation, which can strain resources and slow progress in the market. These challenges collectively impede the scalability and accessibility of gene silencing solutions.

Key Players:

Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Dicerna Pharmaceuticals, Arcturus Therapeutics, Benitec Biopharma, Marina Biotech, Quark Pharmaceuticals, Sirnaomics, RXi Pharmaceuticals, Genevant Sciences, Calando Pharmaceuticals, Regulus Therapeutics, Gradalis, Atalanta Therapeutics, Stoke Therapeutics, Wave Life Sciences, ProQR Therapeutics, Bio-Path Holdings

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Mode
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Short Interfering RNA (siRNA)
    • 4.1.2 MicroRNA (miRNA)
    • 4.1.3 Short Hairpin RNA (shRNA)
    • 4.1.4 Antisense Oligonucleotides (ASO)
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Reagents
    • 4.2.2 Instruments
    • 4.2.3 Kits
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Gene Silencing Research
    • 4.3.2 Custom Synthesis
    • 4.3.3 Consultation
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 RNA Interference (RNAi)
    • 4.4.2 CRISPR-Cas9
    • 4.4.3 Antisense Technology
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Drug Discovery and Development
    • 4.5.2 Functional Genomics
    • 4.5.3 Disease Diagnostics
    • 4.5.4 Therapeutics
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Academic and Research Institutes
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Vectors
    • 4.7.2 Transfection Reagents
    • 4.7.3 Delivery Vehicles
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 In Vitro
    • 4.8.2 In Vivo
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 Direct
    • 4.9.2 Indirect
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Discovery
    • 4.10.2 Preclinical
    • 4.10.3 Clinical
    • 4.10.4 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Process
      • 5.2.1.9 Mode
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Process
      • 5.2.2.9 Mode
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Process
      • 5.2.3.9 Mode
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Process
      • 5.3.1.9 Mode
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Process
      • 5.3.2.9 Mode
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Process
      • 5.3.3.9 Mode
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Process
      • 5.4.1.9 Mode
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Process
      • 5.4.2.9 Mode
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Process
      • 5.4.3.9 Mode
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Process
      • 5.4.4.9 Mode
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Process
      • 5.4.5.9 Mode
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Process
      • 5.4.6.9 Mode
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Process
      • 5.4.7.9 Mode
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Process
      • 5.5.1.9 Mode
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Process
      • 5.5.2.9 Mode
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Process
      • 5.5.3.9 Mode
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Process
      • 5.5.4.9 Mode
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Process
      • 5.5.5.9 Mode
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Process
      • 5.5.6.9 Mode
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Process
      • 5.6.1.9 Mode
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Process
      • 5.6.2.9 Mode
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Process
      • 5.6.3.9 Mode
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Process
      • 5.6.4.9 Mode
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Process
      • 5.6.5.9 Mode
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Alnylam Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Ionis Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Arrowhead Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Silence Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Dicerna Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Arcturus Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Benitec Biopharma
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Marina Biotech
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Quark Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Sirnaomics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 RXi Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Genevant Sciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Calando Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Regulus Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Gradalis
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Atalanta Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Stoke Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Wave Life Sciences
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 ProQR Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Bio-Path Holdings
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us